Search
A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller
- blonca9
- Jan 10, 2024
- 1 min read
Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer at ASCO in 2022.
